Skip to main content

brimonidine (Mirvaso®)

 

Following a full submission

AWMSG advice

Status: Recommended with restrictions

Brimonidine (Mirvaso®) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso®) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso®) is not recommended for use within NHS Wales outside of this subpopulation.

 Final Recommendation: brimonidine (Mirvaso) 2168 (PDF, 277Kb)
 Appraisal Report: brimonidine (Mirvaso) 2168 (PDF, 221Kb)

Medicine details

Medicine name brimonidine (Mirvaso®)
Formulation 3 mg/g gel
Reference number 2168
Indication

Symptomatic treatment of facial erythema of rosacea in adult patients

Company Galderma (UK) Ltd
BNF chapter Skin
Assessment type Full
Status Recommended with restrictions
Advice number 2015
NMG meeting date 10/06/2015
AWMSG meeting date 15/07/2015
Ratification by Welsh Government 27/08/2015
Date of issue 02/09/2015
Date of last review 21/03/2019
Follow AWTTC: